ZEDIRA GMBH
The Darmstadt-based biotech company has a focus on Celiac Disease and other transglutaminase-linked conditions in the arena of autoimmunity, fibrotic diseases, and thrombosis. The company develops, produces, and markets specialty reagents and kits for research and development as well as for clinical diagnostics. Zedira established a pipeline of drug candidates adapted to specific indications based on a series of patented low-molecular transglutaminase blockers. ZED1227 is the first direct-acting transglutaminase inhibitor in clinical development. Zedira is a portfolio company of the German High-Tech Gründerfonds.
Country/Area ：Germany
Company Email ：admin@zedira.com
Industry ：BiotechnologyBusiness ServicesBusiness Services General
Company address ：ROESSLERSTRASSE DARMSTADT 64293
Company website ：*****
Company phone ：+49 6151325100
Established ：2007
Company Revenue ：$4,208,000
Number of employees ：<25
SIC Code ：87873
NAICS Code ：54541
Main Products ：TrideginMicrobial transglutaminaseAndracon™ZED1227
Company News
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Oct 20, 2022
OSAKA, Japan & FREIBURG, Germany & DARMSTADT, Germany--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK), Zedira and Dr. Falk Pharma GmbH today announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease. TAK-227 is a potential first-in-class therapy designed to prevent the immune response to gluten in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage to t
Oct 20, 2022
Web Summary
Q1: What is the address of Zedira GmbH?
A1: The address of Zedira GmbH is Darmstadt, Germany.
Q2: What products does Zedira GmbH offer?
A2: Zedira GmbH offers recombinant microbial transglutaminase (Andracon), a reliable tool for site-specific ADC-production and beyond.
Q3: In which industry is Zedira GmbH operating?
A3: Zedira GmbH operates in the field of medicine, specifically in the development of treatments for Celiac Disease and Transglutaminase-related disorders.
Q4: What services does Zedira GmbH provide?
A4: Zedira GmbH provides business development services, as well as career opportunities, to support its research and innovation efforts.
Q5: How can one contact Zedira GmbH?
A5: One can contact Zedira GmbH through their website, email address (not provided), or by visiting their table booth at the Tampere Celiac Disease Symposium 2025 in Tampere, Finland.
Q6: What is the name of the first-in-class celiac disease therapy being developed by Zedira GmbH?
A6: The first-in-class celiac disease therapy being developed by Zedira GmbH is called ZED1227 (TAK-227), a tissue transglutaminase inhibitor.
Q7: In what year did Zedira GmbH successfully recertify its ISO 9001:2015 quality management system?
A7: Zedira GmbH successfully recertified its ISO 9001:2015 quality management system in the year 2022.
Q8: What is the name of the collaboration and licensing agreement between Takeda, Zedira GmbH, and Dr. Falk Pharma to develop a first-in-class celiac disease therapy?
A8: The collaboration and licensing agreement between Takeda, Zedira GmbH, and Dr. Falk Pharma is called Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie.
A1: The address of Zedira GmbH is Darmstadt, Germany.
Q2: What products does Zedira GmbH offer?
A2: Zedira GmbH offers recombinant microbial transglutaminase (Andracon), a reliable tool for site-specific ADC-production and beyond.
Q3: In which industry is Zedira GmbH operating?
A3: Zedira GmbH operates in the field of medicine, specifically in the development of treatments for Celiac Disease and Transglutaminase-related disorders.
Q4: What services does Zedira GmbH provide?
A4: Zedira GmbH provides business development services, as well as career opportunities, to support its research and innovation efforts.
Q5: How can one contact Zedira GmbH?
A5: One can contact Zedira GmbH through their website, email address (not provided), or by visiting their table booth at the Tampere Celiac Disease Symposium 2025 in Tampere, Finland.
Q6: What is the name of the first-in-class celiac disease therapy being developed by Zedira GmbH?
A6: The first-in-class celiac disease therapy being developed by Zedira GmbH is called ZED1227 (TAK-227), a tissue transglutaminase inhibitor.
Q7: In what year did Zedira GmbH successfully recertify its ISO 9001:2015 quality management system?
A7: Zedira GmbH successfully recertified its ISO 9001:2015 quality management system in the year 2022.
Q8: What is the name of the collaboration and licensing agreement between Takeda, Zedira GmbH, and Dr. Falk Pharma to develop a first-in-class celiac disease therapy?
A8: The collaboration and licensing agreement between Takeda, Zedira GmbH, and Dr. Falk Pharma is called Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
